Dr. Gary S. Jacob, Chief Executive Officer of OKYO discusses the latest from the dry eye treatment company regarding positive results of OK-201, a non-opioid analgesic drug candidate. He also runs through developments at OKYO since he became CEO earlier this year, as well as timelines to future milestones at the company.
Okyo Pharma and the roadmap to IND submission to the FDA for dry eye treatment in 2022
May 6, 2021Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.